Citius Oncology Inc (CTOR)

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin...

Form DEF 14C - Other definitive information statements

Form S-3 - Registration statement under Securities Act of 1933

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report